Smyth, Mark J <br/><br/>
Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Apr 2016 
 - e104-6 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2013.51.3572  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bone Neoplasms--drug therapy<br/>Brain Neoplasms--secondary<br/>CTLA-4 Antigen--antagonists & inhibitors<br/>Denosumab--therapeutic use<br/>Female<br/>Humans<br/>Ipilimumab<br/>Lymphatic Metastasis<br/>Melanoma--drug therapy<br/>Positron-Emission Tomography<br/>Proto-Oncogene Proteins B-raf--genetics<br/>RANK Ligand--antagonists & inhibitors<br/>Skin Neoplasms--drug therapy<br/>Time Factors<br/>Treatment Outcome<br/>Whole Body Imaging--methods